NASDAQ:BFRA

Biofrontera (BFRA) Stock Price, News & Analysis

Notice: This company has been marked as potentially delisted and may not be actively trading.
Today's Range
$2.51
$2.78
50-Day Range
$2.50
$3.60
52-Week Range
$2.09
$7.54
Volume
7,263 shs
Average Volume
27,512 shs
Market Capitalization
$73.73 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
BFRA stock logo

About Biofrontera Stock (NASDAQ:BFRA)

Biofrontera AG engages in the development, sale and distribution of dermatological drugs and medical cosmetics for the care, protection and treatment of the skin. Its products include Ameluz, BF-RhodolesXepi and Belixos. The company was founded by Hermann Lübbert in 1997 and is headquartered in Leverkusen, Germany.

BFRA Stock News Headlines

Biofrontera plant eine Finanzierungsrunde
Exposed: 10 CENT Crypto to Explode April 20th?
The man who bought Bitcoin and Ethereum in 2017… and has spotted 44 different coins that have returned over 100%... Is now exposing a 10-cent coin that just partnered with Amazon…
Q4 2023 Biofrontera Inc Earnings Call
Biofrontera Inc BFRI
What's Going On With Biofrontera Stock?
Exposed: 10 CENT Crypto to Explode April 20th?
The man who bought Bitcoin and Ethereum in 2017… and has spotted 44 different coins that have returned over 100%... Is now exposing a 10-cent coin that just partnered with Amazon…
Biofrontera Shares Rise on Maruho Settlement
Biofrontera AG B8F
See More Headlines
Receive BFRA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Biofrontera and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/24/2021
Today
4/25/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical Preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:BFRA
Employees
138
Year Founded
N/A

Profitability

Net Income
$-14,880,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$36.19 million
Book Value
$0.35 per share

Miscellaneous

Free Float
N/A
Market Cap
$73.73 million
Optionable
Not Optionable
Beta
1.02
13 Stocks Institutional Investors Won't Stop Buying Cover

Which stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.

Get This Free Report

BFRA Stock Analysis - Frequently Asked Questions

How were Biofrontera's earnings last quarter?

Biofrontera AG (NASDAQ:BFRA) issued its earnings results on Wednesday, November, 24th. The company reported ($0.24) earnings per share for the quarter, missing the consensus estimate of ($0.22) by $0.03. The company had revenue of $6.34 million for the quarter. Biofrontera had a negative net margin of 59.44% and a negative trailing twelve-month return on equity of 93.31%.

What other stocks do shareholders of Biofrontera own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Biofrontera investors own include AbbVie (ABBV), Gilead Sciences (GILD), Sorrento Therapeutics (SRNE), Vaxart (VXRT), Adaptimmune Therapeutics (ADAP), GW Pharmaceuticals (GWPH), Pfizer (PFE), Alnylam Pharmaceuticals (ALNY) and Ascendis Pharma A/S (ASND).

When did Biofrontera IPO?

Biofrontera (BFRA) raised $18 million in an initial public offering on Wednesday, February 14th 2018. The company issued 1,500,000 shares at a price of $11.00-$13.00 per share. Benchmark served as the underwriter for the IPO and Dawson James Securities and Lake Street Capital Markets were co-managers.

This page (NASDAQ:BFRA) was last updated on 4/25/2024 by MarketBeat.com Staff

From Our Partners